3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
HER2-positive Breast Cancer
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Nuclear Medicine Department, Hospital
6
Magnetic Resonance Spectroscopy
6
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Biopsy
5
Temozolomide
4
Irinotecan
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dinutuximab
2
Cyclophosphamide
2
trametinib
1
tazemetostat
1
talazoparib
1
saponin QA-21V1
1
palbociclib
1
lutetium Lu 177 dotatate
1
irinotecan sucrosofate
1
fludarabine phosphate
1
fludarabine
1
dabrafenib
1
Vincristine
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroblastoma
×
pertuzumab
×
30 days
×
Clear all
No trials found.